At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Budesonide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Acupuncture Therapy for COVID-Related Olfactory Loss
In Brief
A clinical study evaluating Acupuncture Therapy, Budesonide, and 1 other intervention for Olfactory Dysfunction and COVID-19. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in patients who tested positive for COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOlfactory Dysfunction, COVID-19
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedJul 2021
Enrollment StartDec 2021
Primary CompletionApr 2023
Study CompletionJun 2023
TodayJul 2026
First PostedJul 7, 2021
Enrollment StartDec 7, 2021
Primary CompletionApr 21, 2023
Study CompletionJun 9, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.0 years ago
Interventions
Acupuncture Therapydevice
Consists of two treatments per week for five weeks
Budesonidedrug
Twice daily nasal rinses with steroid medication (budesonide)
Olfactory Trainingother
involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)